Tag Archives: Dewpoint Therapeutics

Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More

Amid the bombast of Tuesday’s presidential debate, viewers caught some discussion about the response to the coronavirus pandemic and efforts to develop a COVID-19 vaccine. In the crosstalk, the president made an unsupported claim that we are weeks away from having vaccines. It’s true that some pharmaceutical companies are already manufacturing their COVID-19 vaccine candidates […]

Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More

If it seems like biotech investments have defied the financial headwinds of the pandemic, maybe it’s because they have. In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies. The figures come from the National Venture Capital Association and financial research firm Pitchbook. This week […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Europe blog main, Europe top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Philadelphia Blog Main, Philadelphia Top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Adagio Therapeutics, Adimab, ALX Oncology, Amgen, Anaptys Bio, Andrew Partridge, Arctic Bio, atezolizumab (Tecentriq), Atox Bio, BeiGene, Berkeley Lights, bevacizumab, Biocon, Biotech, Biotech IPOs, Blueprint Medicines, Brittany Bradrick, C4 Therapeutics, cancer, Cancer Drugs, cancer immunotherapy, Cerevel Therapeutics, Chemotherapy, Christopher Slapak, Citius Pharmaceuticals, Claude Knopf, COVID-19, cytodyn, deals, Dennis Mulroy, Dewpoint Therapeutics, Equillium, Eric Loumeau, Eyepoint Pharmaceuticals, Flagship Pioneering, Gilead Sciences, Glympse Bio, Guillaume Pfefer, guselkumab, HIV, Hp Wild Holding, ImCheck Therapeutics, Immunotherapy, Imvax, infectious diseases, Inventiva, investing, Jay Duker, Johnson & Johnson, Jolie Siegel, Kathleen Tregoning, Keith Sullivan, Kiadis Pharma, kidney failure, Kintai Therapeutics, Kronos Bio, leronlimab, Life Sciences, Liver Disease, Mallinckrodt Pharmaceuticals, Merck, ModeRNA, molluscum contagiosum, Morningside Ventures, Myron Czuczman, Nagesh Mahanthappa, National Venture Capital Association, necrotizing soft tissue infection, Neuronetics, New England Journal of Medicine, Nkarta, nonalcoholic steatohepatitis, Norbert Bischofberger, Novartis, Ophthalmology, Ovarian Cancer, Pandion Therapeutics, Phathom Pharmaceuticals, PitchBook, Poseida Therapeutics, pralsetinib, Ray Barlow, Relay Therapeutics, reltecimod, Roche, Scholar Rock, startups, terlipressin, Todd Branning, Tony Kingsley, Turning Point Therapeutics, Vaccine, Verrica Pharmaceuticals, ViaCyte, Vor BioPharma, William McKee | Comments Off

Dewpoint, Merck Team Up to Tackle HIV Using Condensate Know-How

Dewpoint Therapeutics has signed its second biopharma partnership, teaming up with Merck to explore the potential of using its discoveries around “droplets” of biomolecules that form inside cells to create a new HIV treatment. The companies’ aim is an ambitious one: develop a drug candidate that could prove curative, rather than suppress the infection as […]

Posted in Boston, Boston blog main, Boston top stories, Europe blog main, National blog main | Tagged bayer, Biotech, Centers for Disease Control and Prevention, deals, Dewpoint Therapeutics, HIV, Leaps by Bayer, Life Sciences, Merck, Polaris Partners, startups, Venture Capital | Comments Off

Daré Bioscience Inks Deal With Bayer for Non-Hormonal Contraceptive

Daré Bioscience launched in 2015 with the aim of assembling a portfolio of novel women’s health products intended to pique interest from major pharmaceutical companies. Now the San Diego-based company has inked its first deal with Big Pharma, signing an agreement with German biopharma Bayer for its lead asset, a monthly non-hormonal form of birth […]

Posted in Europe blog main, National blog main, San Diego, San Diego blog main, San Diego top stories | Tagged bayer, Biotech, clinical trials, deals, Dewpoint Therapeutics, Evofem, licensing, Life Sciences, startups | Comments Off

Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More

Lung injuries connected to the use of electronic cigarettes have topped 2,000 and killed 40 people, according to the Centers for Disease Control and Prevention. It’s still unclear whether the cases are tied to legally sold products or devices modified by e-cigarette users, but the CDC this week identified a “potential toxin of concern”—Vitamin E […]

Posted in Boston blog main, Boulder/Denver blog main, Detroit blog main, Indiana blog main, National, National blog main, National top stories, New York blog main, Raleigh-Durham blog main, San Diego blog main, San Francisco blog main, Seattle blog main, Texas blog main, Wisconsin blog main | Tagged Acceleron Pharma, Alport syndrome, Altria, Amarin, Anemia, Anthony Fernando, Aspen Global Incorporated, Astellas, Astellas Pharma, Avalon Ventures, Avidity Biosciences, bayer, Biotech, Bruce Steel, Calporta, Celgene, Clear Genetics, clinical trials, Dan Bradbury, Dewpoint Therapeutics, diabetes, e-cigarettes, Equillium, FDA, Fibrogen, Flagship Pioneering, Foamix Pharmaeuticals, Gene Therapy, GlaxoSmithKline, InVitae, IT, Juul, Life Sciences, luspatercept, Menlo Therapeutis, Merck, Mylan, Neurana Pharmaceuticls, nonalcoholic steatohepatitis, Novartis Institutes for Biomedical Research, Novo Nordisk, Pfizer, Prakash Raman, Promedior, Randall Kaye, Reata, Reata Pharmaceuticals, RegenxBio, RoboticsAI, Roche, Sarepta Therapeutics, Software, Solid Bio, Solid Biosciences, StrideBio, TransEnterix, Ube Industries, Upjohn, Vaccine, Vascepa, Viatris, X-37 | Comments Off

Bayer and Dewpoint Ink Deal for Drugs R&D at New Frontier of Biology

[Updated, 12:15 p.m. See below.] Inside of a cell, some proteins and RNA are concentrated in liquid droplets that assemble in formation during a variety of cellular functions. Dewpoint Therapeutics is making headway understanding the role these droplets play in disease, and that work now has Bayer as a research partner. Bayer and Dewpoint on […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged Anthony Hyman, bayer, biomolecular condensates, Biotech, deals, Dewpoint Therapeutics, Life Sciences, Mark Murcko, Max Planck Institute, Richard Young, startups, Whitehead Institute | Comments Off

Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More

Pharmaceutical companies typically raise prescription drug prices at the start of each year and this year was no different. The increases were the latest reminder that, despite President Trump’s fiery campaign rhetoric, the administration had done little to actually lower drug prices. But a new plan aimed at the secretive rebate deals between pharma companies […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged Abiraterone, AC Immune, Acorda Therapeutics, Aduro BioTech, Agenus, Aldeyra Therapeutics, Aleksandra Rizo, Alexion Pharmaceuticals, Alzheimer's disease, apalutamide, atypical hemolytic uremic syndrome, Bill Cassidy, Biogen, Biotech, Caelum Biosciences, cancer, cancer immunotherapy, Celgene, Chuck Grassley, Corvus Pharmaceuticals, crenezumab, deals, Dengue Fever, Department of Health and Human Services, Dewpoint Therapeutics, drug prices, Eli Lilly, Genentech, Geron, Gossamer Bio, Healio Vision, immunoglobulin light chain amyloidosis, investing, IPO, Johnson & Johnson, Life Sciences, Lyndra Therapeutics, Mark Warner, Medicaid, medicare, Mehrdad Mobasher, MeiraGTx, Neurocrine Biosciences, neurodegeneration, Novartis, Oncocyte, pain drug, Parkinson's Disease, Pfizer, Portola Pharmaceuticals, President Trump, proliferative vitreoretinopathy, rare disease drugs, Ravulizumab, Roche, Sanofi, SEC, Sheldon Koenig, Spinal Muscular Atrophy, startups, Sunovion Pharmaceuticals, Takeda Pharmaceutical, Tanezumab, Trevena, vaccines, Voyager Therapeutics | Comments Off

Dewpoint Debuts with $60M to Target Protein Droplets Linked to Disease

An exciting new area of cell biology research that has emerged in only the last decade has already spawned a startup, which launches today with $60 million in Series A financing. Dewpoint Therapeutics seeks to develop drugs that target a kind of liquid droplet widely found inside cells. These droplets (think bubbles of oil in […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged Alzheimer's, Alzheimer's disease, Amir Nashat, biomolecular condensates, Biotech, cancer, deals, Dewpoint Therapeutics, Drugs, Life Sciences, Mark Murcko, neurodegeneration, phase separation, Polaris Partners, startups, Venture Capital | Comments Off

Tag Archives: Dewpoint Therapeutics

Archives

Meta